Result of AGM

GSK PLC
08 May 2024
 

GSK plc

 

Results of 24th Annual General Meeting

 

GSK plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 8 May 2024 at the Royal Lancaster London, Lancaster Terrace, London, W2 2TY. Shareholders were able to join the meeting in person or virtually via the Lumi AGM website.

 

All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.

 

The table below shows the results of the poll on all 23 resolutions. The full text of the resolutions is contained in the Notice of AGM published on 25 March 2024, which is available on GSK's website at www.gsk.com.

 

Resolution

Total votes for(1)(2)

%

Total votes against(2)

%

Total votes cast

Votes withheld(3)

1

Receive and adopt the 2023 Annual Report

3,026,657,634

99.93

1,985,899

0.07

3,028,643,533

11,560,313

2

Approve the Annual report on remuneration 

2,782,337,600

92.70

219,140,461

7.30

3,001,478,061

38,693,019

3

Election of Wendy Becker

2,908,153,080

95.87

125,392,399

4.13

3,033,545,479

6,609,293

4

Election od Dr Jeannie Lee

3,029,569,885

99.87

4,058,143

0.13

3,033,628,028

6,567,803

5

Re-election of Sir Jonathan Symonds

3,018,694,064

99.51

14,982,162

0.49

3,033,676,226

6,516,614

6

Re-election of Dame Emma Walmsley

3,028,232,685

99.81

5,822,706

0.19

3,034,055,391

6,142,099

7

Re-election of Julie Brown

3,024,167,039

99.68

9,628,961

0.32

3,033,796,000

6,386,918

8

Re-election of Elizabeth McKee Anderson

2,960,185,482

97.57

73,605,787

2.43

3,033,791,269

6,404,117

9

Re-election of Charles Bancroft

3,019,529,985

99.54

13,986,857

0.46

3,033,516,842

6,668,927

10

Re-election of Dr Hal Barron

3,022,032,114

99.61

11,790,927

0.39

3,033,823,041

6,360,307

11

Re-election of Dr Anne Beal

3,021,808,961

99.60

12,038,342

0.40

3,033,847,303

6,336,638

12

Re-election of Dr Harry C Dietz

3,029,031,724

99.85

4,650,326

0.15

3,033,682,050

6,508,974

13

Re-election of Dr Jesse Goodman

3,028,663,561

99.84

4,930,361

0.16

3,033,593,922

6,598,956

14

Re-election of Dr Vishal Sikka

2,868,354,507

94.57

164,801,089

5.43

3,033,155,596

7,017,053

15

Re-appointment of the auditor

3,014,623,759

99.95

1,608,077

0.05

3,016,231,836

23,950,717

16

Remuneration of the auditor

3,031,902,105

99.92

2,552,472

0.08

3,034,454,577

5,710,703

17

Authority for the company to make donations to political organisations and incur political expenditure

2,932,886,023

98.76

36,920,830

1.24

2,969,806,853

70,418,813

18

Authority to allot shares

2,902,088,897

95.68

130,945,918

4.32

3,033,034,815

7,163,455

19

Disapplication of pre-emption rights - general power(4)

2,961,493,840

97.71

69,555,193

2.29

3,031,049,033

9,105,429

20

Disapplication of pre-emption rights - in connection with an acquisition or specified capital investment(4)

2,937,510,909

96.91

93,802,022

3.09

3,031,312,931

8,843,231

21

Authority for the company to purchase its own shares(4)

3,007,905,874

99.25

22,735,155

0.75

3,030,641,029

9,526,430

22

Exemption from statement of senior statutory auditor's name

2,960,435,195

99.72

8,381,561

0.28

2,968,816,756

71,372,939

23

Authority for reduced notice of a general meeting other than an AGM(4)

2,795,236,350

93.79

185,233,215

6.21

2,980,469,565

59,729,307

 

 

Notes:

 

(1)      The "for" votes include those giving the Chair discretion.

(2)      Votes "for" and "against" are expressed as a percentage of the total votes cast.

(3)      A "vote withheld" is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.

(4)      Indicates Special Resolutions requiring a 75% majority of votes cast.

 

The Company's issued share capital as at 3 May 2024 consisted of 4,144,937,355 shares of 31 ¼ pence each ('Ordinary Shares') excluding Ordinary Shares held in Treasury. Every shareholder has one vote for every Ordinary Share held.

 

The above poll results will shortly be available on the company's website at www.gsk.com.

 

In accordance with Listing Rule 9.6.2 of the Financial Conduct Authority's (FCA) Listing Rules, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the FCA and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism

 

 

V A Whyte

Company Secretary

8 May 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

GSK (GSK)
UK 100